NeuCyte Licenses Its Novel Neuronal Programming Technology to Enable Academic Research

Monday, December 3, 2018 Research News
Email Print This Page Comment bookmark
Font : A-A+

SUNNYVALE, Calif., Dec. 3, 2018 /PRNewswire/ -- NeuCyte, Inc., a leading neuroscience drug discovery company, announced that

it has entered a license agreement with Boston Children's Hospital. As part of the agreement, Boston Children's has obtained a non-exclusive license from NeuCyte to manufacture transcription factor Ngn2 programmed induced
neurons. The hospital intends to use this technology for internal research, teaching and educational purposes, and to perform services to other academic institutions.

"We are pleased to license this advantageous technology that was originated from Dr. Thomas Südhof's laboratory at Stanford University," said Mustafa Sahin, MD, PhD, director of the Translational Neuroscience Center and Human Neuron Core at Boston Children's and professor of neurology at Harvard Medical School. "We hope this technology will enable us and other researchers to create a tool that closely resembles human biology in vitro and will become an important part of our effort to improve human health."

"NeuCyte has the exclusive rights to Stanford's original neuronal induction technology and has further developed it to incorporate into our proprietary in vitro drug discovery platforms," said Jonathan Davila, PhD, Co-founder and CEO of NeuCyte. "We are happy to get the technology into the hands of Boston Children's Hospital where it can be further used for academic research. We also welcome discussions with other organizations who are interested in this technology."

About NeuCyte, Inc.NeuCyte is an innovative biotechnology company focused on developing impactful medicines for improving the lives of patients suffering from neurological disorders. Based on its proprietary SynFire® technology for generating human induced pluripotent stem cell (iPSC)-derived induced neural cells, NeuCyte has developed a highly functional in vitro platform for target identification and validation, efficacy testing, neurotoxicity assessment, and disease modeling. With the vast knowledge brought by its staff and scientific advisory board, NeuCyte is actively pursuing drug discovery programs for the treatment of Fragile X Syndrome, Epilepsy, ALS and more.

Contact:Ji Wu1230 Bordeaux DriveSunnyvale, CA 94089ji.wu@neucyte.com

 

Cision View original content:http://www.prnewswire.com/news-releases/neucyte-licenses-its-novel-neuronal-programming-technology-to-enable-academic-research-300757896.html

SOURCE NeuCyte, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store